Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis

AIMS: To evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF). METHODS AND RESULTS: We reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset ≤7 days. We used a random-effects model...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Europace
Autors principals: McIntyre, William F, Healey, Jeff S, Bhatnagar, Akash K, Wang, Patrick, Gordon, Jacob A, Baranchuk, Adrian, Deif, Bishoy, Whitlock, Richard P, Belley-Côté, Émilie P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6680366/
https://ncbi.nlm.nih.gov/pubmed/31292622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euz175
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars